|
1
|
Coresh J, Selvin E, Stevens LA, Manzi J,
Kusek JW, Eggers P, Van ente F and Levey AS: Prevalence of chronic
kidney disease in the United States. JAMA. 298:2038–2047. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Centers for Disease Control and
Prevention: Prevalence of chronic kidney disease and associated
risk factors - United States, 1999–2004. MMWR Morb Mortal Wkly Rep.
56:161–165. 2007.PubMed/NCBI
|
|
3
|
Melamed ML, Eustace JA, Plantinga L, Jaar
BG, Fink NE, Coresh J, Klag MJ and Powe NR: Changes in serum
calcium, phosphate, and PTH and the risk of death in incident
dialysis patients: A longitudinal study. Kidney Int. 70:351–357.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Levin A, Bakris GL, Molitch M, Smulders M,
Tian J, Williams LA and Andress DL: Prevalence of abnormal serum
vitamin D, PTH, calcium, and phosphorus in patients with chronic
kidney disease: Results of the study to evaluate early kidney
disease. Kidney Int. 71:31–38. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moe S, Drüeke T, Cunningham J, Goodman W,
Martin K, Olgaard K, Ott S, Sprague S, Lameire N and Eknoyan G:
Kidney Disease: Improving Global Outcomes (KDIGO): Definition,
evaluation, and classification of renal osteodystrophy: A position
statement from Kidney Disease: Improving Global Outcomes (KDIGO).
Kidney Int. 69:1945–1953. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cunningham J, Locatelli F and Rodriguez M:
Secondary hyperparathyroidism: Pathogenesis, disease progression,
and therapeutic options. Clin J Am Soc Nephrol. 6:913–921. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Andress DL, Coyne DW, Kalantar-Zadeh K,
Molitch ME, Zangeneh F and Sprague SM: Management of secondary
hyperparathyroidism in stages 3 and 4 chronic kidney disease.
Endocr Pract. 14:18–27. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fukagawa M, Hamada Y, Nakanishi S and
Tanaka M: The kidney and bone metabolism: Nephrologists' point of
view. J Bone Miner Metab. 24:434–438. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li J, Molnar MZ, Zaritsky JJ, Sim JJ,
Streja E, Kovesdy CP, Salusky I and Kalantar-Zadeh K: Correlates of
parathyroid hormone concentration in hemodialysis patients. Nephrol
Dial Transplant. 28:1516–1525. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu S, Guo R, Simpson LG, Xiao ZS, Burnham
CE and Quarles LD: Regulation of fibroblastic growth factor 23
expression but not degradation by PHEX. J Biol Chem.
278:37419–37426. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Riminucci M, Collins MT, Fedarko NS,
Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T,
Econs MJ, et al: FGF-23 in fibrous dysplasia of bone and its
relationship to renal phosphate wasting. J Clin Invest.
112:683–692. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shimada T, Hasegawa H, Yamazaki Y, Muto T,
Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S and Yamashita
T: FGF-23 is a potent regulator of vitamin D metabolism and
phosphate homeostasis. J Bone Miner Res. 19:429–435. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Slatopolsky E, Brown A and Dusso A:
Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl.
73(S73): S14–S19. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Anderson JL, Vanwoerkom RC, Horne BD, Bair
TL, May HT, Lappé DL and Muhlestein JB: Parathyroid hormone,
vitamin D, renal dysfunction, and cardiovascular disease: Dependent
or independent risk factors? Am Heart J. 162:331–339.e2. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
National Kidney Foundation: K/DOQI
clinical practice guidelines for bone metabolism and disease in
chronic kidney disease. Am J Kidney Dis. 42(4 Suppl 3): S1–S201.
2003.PubMed/NCBI
|
|
16
|
Orsonneau JL, Douet P, Massoubre C,
Lustenberger P and Bernard S: An improved pyrogallol red-molybdate
method for determining total urinary protein. Clin Chem.
35:2233–2236. 1989.PubMed/NCBI
|
|
17
|
Moe SM, Chertow GM, Coburn JW, Quarles LD,
Goodman WG, Block GA, Drüeke TB, Cunningham J, Sherrard DJ, McCary
LC, et al: Achieving NKF-K/DOQI bone metabolism and disease
treatment goals with cinacalcet HCl. Kidney Int. 67:760–771. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Karsan A, Maclaren I, Conn D and Wadsworth
L: An evaluation of hemoglobin determination using sodium lauryl
sulfate. AmJ Clin Pathol. 100:123–126. 1993. View Article : Google Scholar
|
|
19
|
Drüeke TB: Cell biology of parathyroid
gland hyperplasia in chronic renal failure. J Am Soc Nephrol.
11:1141–1152. 2000.PubMed/NCBI
|
|
20
|
Prince RL: Counterpoint: Estrogen effects
on calcitropic hormones and calcium homeostasis. Endocr Rev.
15:301–309. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li LS and Liu ZH: Epidemiologic data of
renal diseases from a single unit in China: analysis based on
13,519 renal biopsies. Kidney Int. 66:920–923. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsai WC, Wu HY, Peng YS, Ko MJ, Wu MS,
Hung KY, Wu KD, Chu TS and Chien KL: Risk factors for development
and progression of chronic kidney disease: A systematic review and
exploratory meta-analysis. Medicine (Baltimore). 95:e30132016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Staples A and Wong C: Risk factors for
progression of chronic kidney disease. Curr Opin Pediatrics.
22:161–169. 2010. View Article : Google Scholar
|
|
24
|
Ferrier KE, Muhlmann MH, Baguet JP,
Cameron JD, Jennings GL, Dart AM and Kingwell BA: Intensive
cholesterol reduction lowers blood pressure and large artery
stiffness in isolated systolic hypertension. J Am Coll Cardiol.
39:1020–1025. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hruska KA and Mathew S: The roles of the
skeleton and phosphorus in the CKD mineral bone disorder. Adv
Chronic Kidney Dis. 18:98–104. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Voormolen N, Noordzij M, Grootendorst DC,
Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM,
Krediet RT and Dekker FW: PREPARE study group: High plasma
phosphate as a risk factor for decline in renal function and
mortality in pre-dialysis patients. Nephrol Dial Transplant.
22:2909–2916. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Goodman WG and Quarles LD: Development and
progression of secondary hyperparathyroidism in chronic kidney
disease: Lessons from molecular genetics. Kidney Int. 74:276–288.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smith GL, Shlipak MG, Havranek EP, Foody
JM, Masoudi FA, Rathore SS and Krumholz HM: Serum urea nitrogen,
creatinine, and estimators of renal function: mortality in older
patients with cardiovascular disease. Arch Intern Med.
166:1134–1142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kidney Disease; Improving Global Outcomes
(KDIGO)CKD-MBD Work Group: KDIGO clinical practice guideline for
the diagnosis, evaluation, prevention, and treatment of Chronic
Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int.
76(Suppl 113): S1–S130. 2009.
|
|
30
|
Ortega LM and Arora S: Metabolic acidosis
and progression of chronic kidney disease: incidence, pathogenesis,
and therapeutic options. Nefrologia. 32:724–730. 2012.PubMed/NCBI
|
|
31
|
Kovesdy CP: Metabolic acidosis and kidney
disease: does bicarbonate therapy slow the progression of CKD?
Nephrol Dial Transplant. 27:3056–3062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Disthabanchong S, Martin KJ, McConkey CL
and Gonzalez EA: Metabolic acidosis up-regulates PTH/PTHrP
receptors in UMR 106-01 osteoblast-like cells. Kidney Int.
62:1171–1177. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lavín-Gómez BA, Palomar-Fontanet R,
Gago-Fraile M, Quintanar-Lartundo JA, Gómez-Palomo E,
González-Lamuño D, García-Unzueta MT, Arias-Rodríguez MA and
Gómez-Gerique JA: Inflammation markers, chronic kidney disease, and
renal replacement therapy. Adv Perit Dial. 27:33–37.
2011.PubMed/NCBI
|
|
34
|
Tsirpanlis G, Bagos P, Ioannou D, Bleta A,
Marinou I, Lagouranis A, Chatzipanagiotou S and Nicolaou C:
Exploring inflammation in hemodialysis patients: Persistent and
superimposed inflammation. A longitudinal study. Kidney Blood Press
Res. 27:63–70. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ojeda R and Aljama PA: Chronic
microinflammation and endothelial damage in uremia. Nefrologia.
28:583–586. 2008.(In Spanish). PubMed/NCBI
|
|
36
|
Shimada K, Kawarabayashi T, Tanaka A,
Fukuda D, Nakamura Y, Yoshiyama M, Takeuchi K, Sawaki T, Hosoda K
and Yoshikawa J: Oolong tea increases plasma adiponectin levels and
low-density lipoprotein particle size in patients with coronary
artery disease. Diabetes Res Clin Pract. 65:227–234. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Iseki K and Kohagura K: Anemia as a risk
factor for chronic kidney disease. Kidney Int Suppl. S4–S9. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Urena P, Eckardt KU, Sarfati E, Zingraff
J, Zins B, Roullet JB, Roland E, Drüeke T and Kurtz A: Serum
erythropoietin and erythropoiesis in primary and secondary
hyperparathyroidism: Effect of parathyroidectomy. Nephron.
59:384–393. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Drüeke TB and Eckardt KU: Role of
secondary hyperparathyroidism in erythropoietin resistance of
chronic renal failure patients. Nephrol Dial Transplant. 17(Suppl
5): 28–31. 2002. View Article : Google Scholar
|
|
40
|
Strutz F and Zeisberg M: Renal fibroblasts
and myofibroblasts in chronic kidney disease. J Am Soc Nephrol.
17:2992–2998. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Attman PO, Samuelsson O and Alaupovic P:
Lipoprotein metabolism and renal failure. Am J Kidney Dis.
21:573–592. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bobulescu IA: Renal lipid metabolism and
lipotoxicity. Curr Opin Nephrol Hypertens. 19:393–402. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sandhu S, Wiebe N, Fried LF and Tonelli M:
Statins for improving renal outcomes: A meta-analysis. J Am Soc
Nephrol. 17:2006–2016. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Morena M, Cristol JP, Senécal L,
Leray-Moragues H, Krieter D and Canaud B: Oxidative stress in
hemodialysis patients: Is NADPH oxidase complex the culprit? Kidney
Int Suppl. 61:109–114. 2002. View Article : Google Scholar
|
|
45
|
Williams ME: Chronic kidney disease/bone
and mineral metabolism: the imperfect storm. Semin Nephrol.
29:97–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bover J, Aguilar A, Baas J, Reyes J,
Lloret MJ, Farré N, Olaya M, Canal C, Marco H, Andrés E, Trinidad P
and Ballarin J: Calcimimetics in the chronic kidney disease-mineral
and bone disorder. Int J Artif Organs. 32:108–121. 2009.PubMed/NCBI
|
